Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11,247 GBX | -0.03% | +3.38% | +6.09% |
10:50am | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
10:12am | AstraZeneca: Voydeya approved in the EU as a treatment for HPN | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.09% | 215B | |
+25.46% | 659B | |
+25.83% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+8.08% | 210B | |
-6.22% | 200B | |
-8.79% | 149B | |
-5.59% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Partner Daiichi Sankyo Says Type II Variation Application for Breast Cancer Drug Accepted for EMA Review